These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 688611)
81. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Jordan VC Breast Cancer Res Treat; 1982; 2(2):123-38. PubMed ID: 6184101 [TBL] [Abstract][Full Text] [Related]
82. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Jordan VC Breast Cancer Res Treat; 1988 Jul; 11(3):197-209. PubMed ID: 3048447 [TBL] [Abstract][Full Text] [Related]
83. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Lønning PE; Lien EA; Lundgren S; Kvinnsland S Clin Pharmacokinet; 1992 May; 22(5):327-58. PubMed ID: 1505141 [TBL] [Abstract][Full Text] [Related]
84. Identification of products formed during UV irradiation of tamoxifen and their use for fluorescence detection in high-performance liquid chromatography. Salamoun J; Macka M; Nechvátal M; Matousek M; Knesel L J Chromatogr; 1990 Aug; 514(2):179-87. PubMed ID: 2258394 [TBL] [Abstract][Full Text] [Related]
85. Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma. Golander Y; Sternson LA J Chromatogr; 1980 Jan; 181(1):41-9. PubMed ID: 7364914 [TBL] [Abstract][Full Text] [Related]
86. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients. Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101 [TBL] [Abstract][Full Text] [Related]
87. Development of a high-performance liquid chromatography method with fluorescence detection for the routine quantification of tamoxifen, endoxifen and 4-hydroxytamoxifen in plasma from breast cancer patients. Rangel-Méndez JA; Graniel-Sabido MJ; Sánchez-Cruz JF; Moo-Puc R Biomed Chromatogr; 2019 Apr; 33(4):e4462. PubMed ID: 30536934 [TBL] [Abstract][Full Text] [Related]
88. Clinical analysis of tamoxifen, an anti-neoplastic agent, in plasma. Mendenhall DW; Kobayashi H; Shih FM; Sternson LA; Higuchi T; Fabian C Clin Chem; 1978 Sep; 24(9):1518-24. PubMed ID: 688611 [TBL] [Abstract][Full Text] [Related]
89. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review. Teunissen SF; Rosing H; Schinkel AH; Schellens JH; Beijnen JH Anal Chim Acta; 2010 Dec; 683(1):21-37. PubMed ID: 21094378 [TBL] [Abstract][Full Text] [Related]